Show
Sort by
-
- Journal Article
- A1
- open access
Interleukin-1 as innate mediator of T cell immunity
-
- Journal Article
- A1
- open access
Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication
-
- Journal Article
- A1
- open access
Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant
-
A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment